{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"183"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The number of all participants with PD-L1 ≥1% CPS who discontinued study treatment due to an AE is presented.","groups":[{"description":"Participants received pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received standard treatment of either methotrexate 40 mg/m\\^2 IV (could be escalated to 60 mg/m\\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m\\^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m\\^2 IV loading dose on Day 1 and 250 mg/m\\^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m\\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.","id":"OG001","title":"Standard Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population consisted of all randomized participants with PD-L1 ≥1% CPS who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 30 months","title":"Number of Participants Who Discontinued Study Treatment Due to an AE in Participants With PD-L1 ≥1% CPS","type":"SECONDARY","unitOfMeasure":"Participants"}